medigraphic.com

2023, Number 2

<< Back Next >>

Rev Fac Med UNAM 2023; 66 (2)

DRESS, a Non-IgE Mediated Allergic Reaction

Pavón-Romero GF, Gutiérrez-Quiroz KV, Ramírez-Jiménez F, Rosas-Fernández R, Parra-Vargas MI, Terán LM

Language: Spanish
References: 40
Page: 7-19
PDF size: 470.07 Kb.


ABSTRACT

DRESS (drug reaction syndrome with eosinophilia and systemic symptoms) is a rare drug-induced multisystemic hypersensitivity response that can induce a severe cutaneous adverse reaction that is difficult to diagnose and treat. It frequently manifests as an extensive skin rash, systemic symptoms, lymphadenopathy, visceral organ involvement, and hematological alterations, mainly leukocytosis, eosinophilia, and sometimes atypical lymphocytosis that manifest 2 to 8 weeks after continuous administration of the responsible drug. The most prevalent drugs related with this syndrome are phenytoin, carbamazepine, allopurinol, and abacavir. Some specific human leukocyte antigen (HLA) alleles have been identified that are associated with hypersensitivity to these drugs. The pathophysiology of DRESS syndrome is not yet fully understood; the main hypothesis is a T-cell mediated hypersensitivity response when interacting with the major histocompatibility complex receptor in individuals with genetic susceptibility factors. The criteria of the European Registry of Severe Cutaneous Adverse Reactions to Drugs (RegiSCAR) are the most commonly used for the diagnosis of DRESS syndrome. Drug-induced hypersensitivity syndrome (DiHS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP) should be considered for any rash that appears following the administration of any drug. Therapy of DRESS includes the elimination of the causative agent as soon as possible, as well as systemic corticosteroids which are the cornerstones of treatment. Steroid-sparing agents such as cyclosporine, intravenous immunoglobulins (IVIGs), and other immunosuppressive agents have been used successfully to contribute to treatment.


REFERENCES

  1. Sharma VK, Sethuraman G, Kumar B. Cutaneous adversedrug reactions: Clinical pattern and causative agents - A6 year series from Chandigarh, India. J Postgrad Med. 2001;47(2):95-9.

  2. Johansson SGO, Bieber T, Dahl R, Friedmann PS, LanierBQ, Lockey RF, et al. Revised nomenclature for allergy forglobal use: Report of the Nomenclature Review Committeeof the World Allergy Organization, October 2003. J AllergyClin Immunol. 2004;113(5):832-6.

  3. Demoly P, Adkinson NF, Brockow K, Castells M, ChiriacAM, Greenberger PA, et al. International Consensus ondrug allergy. Allergy. 2014;69(4):420-37.

  4. Dykewicz MS, Lam JK. Drug Hypersensitivity Reactions.Med Clin North Am. 2020;104(1):109-28.

  5. Dispenza MC. Classification of hypersensitivity reactions.Allergy Asthma Proc. 2019;40(6):470-3.

  6. Chua KYL, Vogrin S, Bury S, Douglas A, Holmes NE,Tan N, et al. The Penicillin Allergy Delabeling Program:A Multicenter Whole-of-Hospital Health Services Interventionand Comparative Effectiveness Study. Clin InfectDis. 2021;73(3):487-96.

  7. Mancini CM, Fu X, Zhang Y, Kuper K, Schulz LT, BhowmickT, et al. Penicillin Allergy Evaluation Access: A NationalSurvey. Clin Infect Dis. 2020;71(11):2972-5.

  8. Staicu ML, Vyles D, Shenoy ES, Stone CA, Banks T, AlvarezKS, et al. Penicillin Allergy Delabeling: A MultidisciplinaryOpportunity. J Allergy Clin Immunol Pract.2020;8(9):2858-2868.e16.

  9. Waheed A, Hill T, Dhawan N. Drug Allergy. Prim Care -Clin Off Pract. 2016;43(3):393-400.

  10. De A, Rajagopalan M, Sarda A, Das S, Biswas P, De Abhishek,Rajagopalan Murlidhar, Sarda Aarti, Das Sudip BProjna,et al. Drug reaction with eosinophilia and systemicsymptoms: An update and review of recent literature. IndianJ Dermatol. 2018;63(1):30-40.

  11. Bommersbach TJ, Lapid MI, Leung JG, CunninghamJL, Rummans TA, Kung S. Management of PsychotropicDrug-Induced DRESS Syndrome: A Systematic Review.Mayo Clin Proc. 2016;91(6):787-801.

  12. Mori F, Caffarelli C, Caimmi S, Bottau P, Liotti L, Frances-chini F, et al. Drug reaction with eosinophilia and systemicsymptoms (DRESS) in children. Acta Biomed. 2019;90(3-S):66-79.

  13. Tashiro Y, Azukizawa H, Asada H, Niihara H, Morita E,Yamauchi T, et al. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptomsdue to lamotrigine differs from that due to other drugs. JDermatol. 2019;46(3):226-33.

  14. Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH.Drug Reaction with Eosinophilia and Systemic Symptoms(DReSS): How Far Have We Come? Am J Clin Dermatol.2019;20(2):217-36.

  15. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, ChuCY, Creamer D, et al. Drug reaction with eosinophilia andsystemic symptoms (DRESS): An original multisystemadverse drug reaction. Results from the prospective RegiSCARstudy. Br J Dermatol. 2013;169(5):1071-80.

  16. Bourneau-Martin D, Leclech C, Jamet A, Drablier G, TrenqueT, Juengel K, et al. Omeprazole-induced drug reactionwith eosinophilia and systemic symptoms (DRESS). Eur JDermatol. 2014;24(3):413-5.

  17. Shiohara T, Kano Y. Drug reaction with eosinophilia andsystemic symptoms (DRESS): incidence, pathogenesis andmanagement. Expert Opin Drug Saf. 2017;16(2):139-47.

  18. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, HuangHP, et al. HLA-B*5801 allele as a genetic marker for severecutaneous adverse reactions caused by allopurinol. ProcNatl Acad Sci U S A. 2005;102(11):4134-9.

  19. Aihara M. Pharmacogenetics of cutaneous adverse drugreactions. J Dermatol. 2011;38(3):246-54.

  20. Man CBL, Kwan P, Baum L, Yu E, Lau KM, Cheng ASH,et al. Association between HLA-B*1502 allele and antiepilepticdrug-induced cutaneous reactions in Han Chinese.Epilepsia. 2007;48(5):1015-8.

  21. Hetherington S, Hughes AR, Mosteller M, Shortino D,Baker KL, Spreen W, et al. Genetic variations in HLA-Bregion and hypersensitivity reactions to abacavir. Lancet.2002;359(9312):1121-2.

  22. Mallal S, Phillips E, Carosi G, Molina JM, Workman C,Tomažič J, et al. HLA-B*5701 screening for hypersensitivityto abacavir. N Engl J Med. 2008;358(6):568-79.

  23. White KD, Chung WH, Hung SI, Mallal S, Phillips EJ.Evolving models of the immunopathogenesis of T-cell mediateddrug allergy: the role of host, pathogens, and drugresponse HHS Public Access. J Allergy Clin Immunol.2015;136(2):219-34.

  24. Negrini S, Becquemont L. HLA-associated drug hypersensitivityand the prediction of adverse drug reactions.Pharmacogenomics. 2017;18(15):1441-57.

  25. Sasidharanpillai S, Ajithkumar K, Jishna P, Khader A,Anagha KV, Binitha MP, et al. RegiSCAR DRESS (DrugReaction with Eosinophilia and Systemic Symptoms) ValidationScoring System and Japanese Consensus GroupCriteria for Atypical Drug-Induced Hypersensitivity Syndrome(DiHS): A Comparative Analysis. Indian DermatolOnline J. 2022;13(1):40-5.

  26. Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes BavinckJN, Halevy S, et al. Comprehensive survival analysis ofa cohort of patients with Stevens-Johnson syndrome and toxicepidermal necrolysis. J Invest Dermatol. 2013;133(5):1197-204.

  27. Peyrière H, Dereure O, Breton H, Demoly P, CociglioM, Blayac JP, et al. Variability in the clinical pattern ofcutaneous side-effects of drugs with systemic symptoms:does a DRESS syndrome really exist? Br J Dermatol. 2006;155(2):422-8.

  28. Chiou CC, Yang LC, Hung SI, Chang YC, Kuo TT, HoHC, et al. Clinicopathological features and prognosis ofdrug rash with eosinophilia and systemic symptoms: a studyof 30 cases in Taiwan. J Eur Acad Dermatol Venereol.2008;22(9):1044-9.

  29. Shiohara T, Mizukawa Y. Drug-induced hypersensitivitysyndrome (DiHS)/drug reaction with eosinophilia and systemicsymptoms (DRESS): An update in 2019. Allergol Int.2019;68(3):301-8.

  30. Phillips EJ, Bigliardi P, Bircher AJ, Broyles A, Chang YS,Chung WH, et al. Controversies in drug allergy: Testing fordelayed reactions. J Allergy Clin Immunol. 2019;143(1):66-73.

  31. Uyesugi BA, Sheehan MP. Patch Testing Pearls. Clin RevAllergy Immunol. 2019;56(1):110-8.

  32. Miyagawa F, Asada H. Current Perspective Regarding theImmunopathogenesis of Drug-Induced HypersensitivitySyndrome/Drug Reaction with Eosinophilia and SystemicSymptoms (DIHS/DRESS). Int J Mol Sci. 2021;22(4):1-13.

  33. Hasegawa A, Abe R. Recent advances in managing andunderstanding Stevens-Johnson syndrome and toxic epidermalnecrolysis. 2020;9:612.

  34. Frantz R, Huang S, Are A, Motaparthi K. Stevens-johnsonsyndrome and toxic epidermal necrolysis: A review of diagnosisand management. 2021;57(9):895.

  35. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JNB,Naldi L, et al. Risk factors for acute generalized exanthematouspustulosis (AGEP)-results of a multinational casecontrolstudy (EuroSCAR). 2007;157(5):989-96.

  36. Mockenhaupt M. Epidemiology of cutaneous adverse drugreactions. 2017;1(1):96-108.

  37. Roujeau JC, Haddad C, Paulmann M, Mockenhaupt M.Management of nonimmediate hypersensitivity reactionsto drugs. 2014;34(3):473-87.

  38. Kirchhof MG, Wong A, Dutz JP. Cyclosporine Treatmentof Drug-Induced Hypersensitivity Syndrome. 2016;152(11):1254-7.

  39. Damsky WE, Vesely MD, Lee AI, Choi J, Meyer AC, Chen M,et al. Drug-induced hypersensitivity syndrome with myocardialinvolvement treated with tofacitinib. 2019; 5(12):1018-26.

  40. Kim D, Kobayashi T, Voisin B, Jo JH, Sakamoto K, Jin SP,et al. Targeted therapy guided by single-cell transcriptomicanalysis in drug-induced hypersensitivity syndrome: a casereport. 2020;26(2):236-43.




2020     |     www.medigraphic.com